secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001558370-25-006150
Event type: other
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes
--------------------------------------------------------------------------------

- BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.
- Data confirm potential of BP1001-A to treat obesity in Type 2 diabetes patients.
- Pre-clinical testing in HepG2 liver cell model supports earlier results in muscle cells.
- Next step: mouse model study; IND filing expected in 2025 for Phase 1 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/0001558370-25-006150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/bpth-20250501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer